Latest news with #R&D
Yahoo
6 hours ago
- Business
- Yahoo
Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ...
Cash Balance: CHF2.8 million as of March 31, 2025. Cash Runway: Expected to last through mid-2026. Continuing R&D Expenses: CHF0.1 million, primarily related to the GABAB PAM program. Continuing G&A Expenses: CHF0.5 million, primarily related to corporate loan activities. Net Loss from Discontinued Operations: Specific line item due to divested business. Current Liabilities: CHF1.1 million as of March 31, 2025. Non-Current Liabilities: CHF0.1 million as of March 31, 2025. Equity Interest: 20% equity interest in a divested business, recorded under non-current assets. Warning! GuruFocus has detected 6 Warning Signs with ADXN. Release Date: June 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Addex Therapeutics Ltd (NASDAQ:ADXN) has made significant progress in its GABAB positive allosteric modulator program with partner Indivior, completing IND-enabling studies for substance use disorders. The company regained rights to its mGluR2 positive allosteric modulator program from Johnson & Johnson, opening new therapeutic opportunities. Addex Therapeutics Ltd (NASDAQ:ADXN) has repositioned its mGluR5 negative allosteric modulator program for brain injury recovery, with promising preclinical data supporting its potential. The company has a strong cash position with CHF2.8 million, providing a runway through mid-2026, and has reduced cash burn following the Neurosterix spinout. Addex Therapeutics Ltd (NASDAQ:ADXN) has a robust pipeline with multiple programs advancing, including a promising candidate for chronic cough with favorable preclinical efficacy and tolerability. The current cash position does not fund the progression of unpartnered programs into the clinic, indicating potential future financing needs. Revenue decreased compared to the previous year due to the completion of the funded research phase with Indivior, impacting financial performance. The company faces competition in the chronic cough market, with existing compounds showing promising efficacy but challenging tolerability profiles. There is uncertainty regarding the clinical development pathway and competitive landscape for the chronic cough program, which could impact future success. Addex Therapeutics Ltd (NASDAQ:ADXN) needs to conduct further studies to optimize the use of dipraglurant in post-stroke rehabilitation, indicating a longer timeline before potential market entry. Q: Can you provide your updated thoughts on the current competitive landscape in chronic cough and the relevance of proceeding programs for your clinical development pathway? A: Mikhail Kalinichev, Head of Translational Science, explained that there are several compounds in development, such as now roofing, which has shown promising efficacy but with tolerability challenges. Addex aims to deliver similar efficacy with improved tolerability, targeting both IPF-related and refractory chronic cough. The development plan includes studies in healthy volunteers and a challenge study in chronic cough patients, followed by a Phase 2 study with advanced monitoring technologies. Q: Can you comment on the potential applicability of your agent for chronic painful cough in indications outside of IPF, like pulmonary sarcoidosis? A: Mikhail Kalinichev noted that chronic painful cough could be a suitable indication due to the sustained activation of GABAB across multiple conditions, including chronic cough. Tim Dyer, CEO, added that they are considering this indication for Phase 2 development. Q: Regarding dipraglurant in post-stroke rehabilitation, what would an appropriate control arm look like in a registration-quality study, and what is the efficacy bar in this indication? A: Mikhail Kalinichev stated that dipraglurant would be used alongside physiotherapy due to its short half-life and good tolerability. They plan to conduct clinical pharmacology studies to understand its modulation effects better, which will inform the design of a Phase 2 study. The efficacy bar is challenging as no pharmacotherapies are currently approved in this context. Q: Can you elaborate on the strategic importance of your GABAB positive allosteric modulator program with Indivior? A: Tim Dyer highlighted the program's potential to deliver a better baclofen for substance use disorders, with a longer half-life and improved side effect profile. The partnership with Indivior is crucial, as it allows Addex to advance its own independent GABAB PAM program for chronic cough, leveraging the strong rationale for GABAB PAMs in this area. Q: What are the financial implications of your recent achievements and strategic partnerships? A: Tim Dyer reported that Addex completed Q1 2025 with CHF2.8 million in cash, providing a runway through mid-2026. The cash burn has been reduced following the Neurosterix spinout, and the company is well-positioned to deliver on strategic objectives, including advancing their pipeline and exploring new partnerships. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Globe and Mail
12 hours ago
- Business
- Globe and Mail
Blood Cell Factors Market Expected to Touch USD 4.31 Bn by 2032, CAGR of 3.6% Detailed in New Report
The global blood cell factors market growth is driven by the increasing prevalence of blood disorders, advancements in healthcare infrastructure, and rising demand for effective treatments. Additionally, growing awareness about blood cell factors and their role in treating various blood-related conditions are expected to fuel the market growth. Blood Cell Factors Market Insights The Blood Cell Factors industry is experiencing robust expansion driven by rising hemophilia treatment demand and novel biologics pipelines. This expert analysis explores market size, dynamics, and actionable insights to guide strategic decision-making in 2025–2032. The Global Blood Cell Factors Market size is estimated to be valued at USD 3.37 Bn in 2025 and is expected to reach USD 4.31 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032. According to the latest Blood Cell Factors market size assessment and Blood Cell Factors market report, global market revenue surpassed USD 3.4 Bn in 2024, indicating an upward shift in market share across major regions. This market forecast underscores expanding industry size and business growth opportunities. Market Key Takeaways: Region: • North America: Strong R&D investments in recombinant factors drive advanced product launches. • Latin America: Rising healthcare infrastructure improvements accelerate treatment adoption. • Europe: Regulatory harmonization fosters cross-border supply chains. • Asia Pacific: Expanding manufacturing capacity and favorable pricing boost volume. • Middle East: Government-backed hemophilia programs underpin demand growth. • Africa: Emerging import channels and NGO support enhance access. Segment Covers: • Product Type: – Recombinant Factors: Example: Amgen's 2024 launch of Factor VIII rAHFV captured 42% of new biologics uptake. – Plasma-Derived Factors: Sanofi's Purified FVIII retains stable pricing leadership in 2025. – Gene Therapy Platforms: Early-stage pipelines by Regeneron target one-dose cures. • Application: – Hemophilia A/B: Eli Lilly's factor IX pegylated formulation grew 28% in 2024 revenues. – Von Willebrand Disease: Pfizer's new multi‐domain VWF therapy gained EMA approval in 2024. • End User: – Hospitals & Clinics: Accounted for 65% of procurement in 2024. – Specialty Centers: Focused infusion protocols drive repeat purchase patterns. Growth Factors: • Rising Prevalence of Coagulation Disorders: The global hemophilia population increased by 4.5% between 2023 and 2024, driving factor consumption. • Strategic Partnerships: In 2024, Roche's collaboration with a biotech startup increased manufacturing capacity by 15% and expanded contract manufacturing revenue by USD 80 Mn. • Blood Cell Factors market share gains hinge on targeted rebates and patient support programs in North America and Europe, lifting volume growth despite pricing pressures. • Increased public funding for rare diseases in Japan and Australia boosted factor adoption by 12% in 2024. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: • Personalized Medicine: Tailored dosing algorithms using AI-driven pharmacokinetic models reduced bleed rates by 30% in 2024 trials. • Biosimilar Entrants: Novartis's pipeline biosimilar of FVIII (expected 2025 launch) is projected to undercut reference pricing by 20%. • Digital Adherence Tools: Mobile infusion tracking apps improved on-time dosing by 18% across 2024 real-world studies. • Blood Cell Factors market trends indicate heightened M&A activity—with Teva's acquisition of a plasma facility in 2024 enhancing Asia Pacific supply by 25%. Actionable Insights: • Production Capacity: Global recombinant factor capacity rose to 150 kg in 2024, up 10% YOY, enabling wider supply. • Pricing Benchmarks: Median USD 0.85/IU for FVIII in Western Europe vs. USD 0.65/IU in Asia Pacific illustrates import-driven discounts. • Exports & Imports: Asia Pacific exported USD 220 Mn of plasma-derived factors in 2024, while Africa imported USD 90 Mn, reflecting demand-supply gaps. • Use-Case Volumes: Hospital procurement volumes for prophylactic regimens grew 14% in Latin America in 2024, outpacing on-demand therapy. • Nano-Indicators: Patient registry expansions in the Middle East added 5,000 new documented cases in 2024, informing localized forecasting models. • Blood Cell Factors market revenue analyses highlight cost-per-patient as a leading macro-indicator for future investment. Key Players: • Amgen Inc. • Johnson & Johnson • Roche Holding AG • Novartis AG • Pfizer Inc. • Bristol-Myers Squibb Company • Eli Lilly Company • Gilead Sciences Inc. • Sanofi S.A. • Merck & Co. Inc. • Teva Pharmaceutical Industries Ltd. • AbbVie Inc. • Celgene Corporation • Takeda Pharmaceutical Company Limited • Regeneron Pharmaceuticals Inc. Get Customization on this Report: Competitive Strategies: – Roche's 2024 capacity partnership with Biogen boosted contract revenues by USD 80 Mn and reduced production costs by 12%. – Novartis's biosimilar rollout strategy undercut reference FVIII pricing by 20%, capturing 8% market share in Europe within six months. – Pfizer's bundled care agreements with specialty clinics in North America in 2024 increased annualized purchases by 22%. Frequently Asked Questions 1. Who are the dominant players in the Blood Cell Factors market? Major players include Amgen, Roche, Novartis, Pfizer, and Sanofi, each commanding significant market share through diversified portfolios and strategic alliances. 2. What will be the size of the Blood Cell Factors market in the coming years? The market is forecast to grow from USD 3.37 Bn in 2025 to USD 4.31 Bn by 2032 at a 3.6% CAGR. 3. Which end-user industry has the largest growth opportunity? Hospitals & clinics represent the largest segment, accounting for over 65% of revenues in 2024, driven by prophylactic treatment mandates. 4. How will market development trends evolve over the next five years? Trends include AI-enabled dosing, gene therapy maturation, and biosimilar price competition, reshaping market dynamics and business growth strategies. 5. What is the nature of the competitive landscape and challenges in the Blood Cell Factors market? Intense R&D races, biosimilar threats, and supply-chain complexities define the competitive landscape, while high manufacturing costs remain a key restraint. 6. What go-to-market strategies are commonly adopted in the Blood Cell Factors market? Strategies include co-development partnerships, patient support services, value-based contracts, and digital adherence platforms to drive uptake and retention. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Yahoo
17 hours ago
- Business
- Yahoo
Clorox's Innovation Strategy Elevates Everyday Essentials
Innovation sits at the core of The Clorox Company's CLX strategy to remain competitive in a category dominated by global giants and cost-effective private labels. It focuses on consumer-centric innovation, wherein improvements in performance, sensory appeal and convenience are key levers. In third-quarter 2025, Clorox highlighted the success of several premium products such as Scentiva disinfecting sprays, the upgraded ToiletWand and odor-control litter, all designed to command a premium while meeting real, evolving consumer needs. This strategy aligns with the company's belief that consumers are still willing to pay more for products that deliver superior value per approach to innovation is both bifurcated and realistic. On one hand, the company is leaning into premiumization across categories to differentiate from private label. On the other hand, it is expanding price-pack architecture to provide budget-conscious consumers with flexible options, such as smaller entry-price packs and value sizes for club and mass channels. Clorox has been disciplined in its promotional strategy, choosing to support innovation through targeted marketing and selective discounting rather than broad-based price cuts. This dual approach allows the company to protect margins while defending its share across income segments and competitive ahead, Clorox remains committed to investing in R&D, supported by tools like its digital transformation and upcoming ERP system upgrade, which will enable more agile innovation and supply chain responsiveness. Despite current market headwinds and volatility in consumer spending, the company sees innovation as a key driver of long-term growth and margin expansion. Clorox's track record of delivering trustworthy, high-performing products in essential categories uniquely positions it to win in both up and down cycles, provided the company continues to innovate where it matters most to consumers. The Procter & Gamble Company PG, Colgate-Palmolive Company CL and Church & Dwight Co., Inc. CHD are the key consumer staple companies competing with Clorox in the global & Gamble uses a smart strategy when it comes to innovation. The company keeps improving its popular brands like Tide, Febreze and Mr. Clean by adding new features, better scents or easier packaging. At the same time, PG gives shoppers different choices depending on their focuses on value-driven innovation, especially in home care and personal hygiene. The company regularly updates products with new scents, improved cleaning formulas and convenient packaging. Colgate also invests in sustainability, such as recyclable bottles and concentrated products. Its innovation is often designed to meet the needs of both budget-conscious and environmentally aware & Dwight is a key competitor to Clorox, known for its value-focused and niche household brands like OxiClean and Arm & Hammer. The company emphasizes cost-effective innovation, often targeting specific consumer needs with affordable, functional products. CHD competes directly with Clorox in laundry additives, cleaning sprays, and baking soda-based solutions. Clorox shares have lost 25.5% year to date compared with the industry's growth of 2.2%. Image Source: Zacks Investment Research From a valuation standpoint, CLX trades at a forward price-to-earnings ratio of 18.0X, significantly below the industry's average of 20.23X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for CLX's 2025 earnings implies year-over-year growth of 14.9%, whereas its 2026 earnings estimate suggests a year-over-year decline of 5.4%. The estimates for 2025 and 2026 have been unchanged in the past 30 days. Image Source: Zacks Investment Research CLX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Colgate-Palmolive Company (CL) : Free Stock Analysis Report The Clorox Company (CLX) : Free Stock Analysis Report Church & Dwight Co., Inc. (CHD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Globe and Mail
18 hours ago
- Business
- Globe and Mail
Medicinal Herbs Market Booming Worldwide, Forecasted to Reach USD 478.93 Bn by 2032 at 11.21% CAGR
The medicinal herbs market is experiencing a significant trend towards the adoption of herbal remedies and supplements for various health conditions such as digestive disorders, respiratory issues, and immune system support. Additionally, the integration of medicinal herbs into functional foods and beverages is gaining traction, as consumers seek convenient ways to incorporate these beneficial ingredients into their daily diets. Medicinal Herbs Market Insights The Medicinal Herbs Market is witnessing accelerated expansion driven by heightened consumer trust in natural therapeutics and increased R&D investments in phytochemical standardization. Robust regulatory support for botanical ingredients and collaborations between extract manufacturers and pharmaceutical companies are reshaping the landscape, reinforcing both market dynamics and industry trends. Market Size and Overview- The Global Medicinal Herbs Market size is estimated to be valued at USD 227.65 billion in 2025 and is expected to reach USD 478.93 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.21% from 2025 to 2032. • This medicinal herbs market size underscores significant industry size expansion and business growth. • A comprehensive market report and market size data reveal pivotal market drivers and market restraints shaping supply chains. Request Sample Copy of this Report (Use Corporate eMail ID to Get Higher Priority) at: Market Key Takeaways Latest medicinal herbs market report highlights: • North America: Advanced clinical trials and strong nutraceutical demand drive innovative extract applications. • Latin America: Rich biodiversity and traditional usage support smallholder cultivation models. • Europe: Stricter quality regulations boost standardized extract production and traceability. • Asia Pacific: Longstanding herbal medicine heritage fuels pharmaceutical and OTC integration. • Middle East: Rising healthcare expenditures and wellness tourism increase botanical consumption. • Africa: Untapped wild-harvest potential balanced by emerging sustainable sourcing initiatives. Segment Covers market segments and subsegments: • Product Type: Leaves (e.g., Echinacea in cold remedies), Roots & Rhizomes (e.g., Ginseng in adaptogens), Seeds & Flowers (e.g., Chamomile in sleep aids). • Application: Pharmaceuticals (standardized extracts for chronic conditions), Nutraceuticals (capsules and tonics), Cosmetics (anti-aging serums). • End User: Hospitals & Clinics (clinical formulations), Household & OTC (teas, supplements). Growth Factors • Expanding medicinal herbs market share is driven by a 9% rise in chronic disease prevalence (WHO, 2024), escalating demand for herbal adjunct therapies. • Increased cultivation acreage—up 8.2% year-on-year to 2.1 million hectares in 2024—enhances supply security and production capacity. • Government incentives in Asia Pacific raised organic herb farms by 15% in 2024, fueling market opportunities and industry share gains. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends • Emergence of green extraction methods—supercritical CO2 adoption rose 15% in 2024—optimizes yield and purity, reflecting current market trends. • Digital traceability platforms for herb sourcing expanded by 30% in 2025, addressing market challenges around quality and counterfeit products. • Co-formulations combining herbs and probiotics are projected to capture 22% of new product launches in 2025, reshaping market opportunities. Actionable Insights • Supply-Side Indicators: Global production capacity reached 3.5 million tons in 2024; average export prices for major herbal extracts climbed 6% Y-o-Y. • Demand-Side Indicators: Imports of dried roots grew 9% in Europe (2024); pharmaceutical application drove 45% of total medicinal herbs market revenue in 2024. • Micro Indicators: Over 120 new herb distillation units commissioned in 2024, boosting regional capacity by 7%. • Nano Indicators: Unit pricing for high-purity flavonoid extracts rose from USD 120 to USD 135 per kg between Q1 and Q4 2024. Key Players • Bio Botanica • Nature's Answer • Nutraceutical Corporation (Bright Food) • Horphag Research (Pycnogenol) • Indena S.p.A • Euromed S.A • Martin Bauer Group • Organic Herb Trading • Starwest Botanicals • Traditional Medicinals • Gaia Herbs • Herb Pharm • MediHerb (Integria Healthcare) • Blackmores • Schwabe Group Get Customization on this Report: Competitive Strategies: • Indena S.p.A invested USD 50 million in R&D for standardized flavonoid extracts in 2024, boosting its medicinal herbs market share by 12% across Europe. • Nature's Answer launched a blockchain-based traceability program in North America in late 2024, enhancing consumer trust and driving a 14% revenue uplift. • Bio Botanica formed strategic distribution partnerships in Asia Pacific in 2025, achieving an 18% surge in regional market revenue within six months. Frequently Asked Questions 1. Who are the dominant players in the Medicinal Herbs Market? Leading market players include Bio Botanica, Indena S.p.A, Nature's Answer, Euromed S.A, and Gaia Herbs, accounting for diversified portfolios and strong R&D. 2. What will be the size of the Medicinal Herbs Market in the coming years? The market forecast projects growth from USD 227.65 billion in 2025 to USD 478.93 billion by 2032 at a CAGR of 11.21%. 3. Which end-user industry has the largest growth opportunity? The pharmaceutical segment, leveraging standardized extracts for chronic therapies, is poised to capture the largest share by 2032, driven by clinical validation. 4. How will market development trends evolve over the next five years? Trends such as green extraction, digital traceability, and co-formulations with probiotics will dominate product innovation and industry share expansions through 2032. 5. What is the nature of the competitive landscape and challenges in the Medicinal Herbs Market? Intense competition among key companies focuses on quality assurance, regulatory compliance, and sustainable sourcing; primary challenges include supply chain variability and fluctuating raw material prices. 6. What go-to-market strategies are commonly adopted in the Medicinal Herbs Market? Leading strategies include blockchain traceability, strategic distribution partnerships, heavy R&D investments, and direct-to-consumer e-commerce platforms to enhance market penetration. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Globe and Mail
20 hours ago
- Business
- Globe and Mail
Clorox's Innovation Strategy Elevates Everyday Essentials
Innovation sits at the core of The Clorox Company 's CLX strategy to remain competitive in a category dominated by global giants and cost-effective private labels. It focuses on consumer-centric innovation, wherein improvements in performance, sensory appeal and convenience are key levers. In third-quarter 2025, Clorox highlighted the success of several premium products such as Scentiva disinfecting sprays, the upgraded ToiletWand and odor-control litter, all designed to command a premium while meeting real, evolving consumer needs. This strategy aligns with the company's belief that consumers are still willing to pay more for products that deliver superior value per use. Clorox's approach to innovation is both bifurcated and realistic. On one hand, the company is leaning into premiumization across categories to differentiate from private label. On the other hand, it is expanding price-pack architecture to provide budget-conscious consumers with flexible options, such as smaller entry-price packs and value sizes for club and mass channels. Clorox has been disciplined in its promotional strategy, choosing to support innovation through targeted marketing and selective discounting rather than broad-based price cuts. This dual approach allows the company to protect margins while defending its share across income segments and competitive environments. Looking ahead, Clorox remains committed to investing in R&D, supported by tools like its digital transformation and upcoming ERP system upgrade, which will enable more agile innovation and supply chain responsiveness. Despite current market headwinds and volatility in consumer spending, the company sees innovation as a key driver of long-term growth and margin expansion. Clorox's track record of delivering trustworthy, high-performing products in essential categories uniquely positions it to win in both up and down cycles, provided the company continues to innovate where it matters most to consumers. Clorox's Competitors in Innovation: PG,CL & CHD's Smart Moves The Procter & Gamble Company PG, Colgate-Palmolive Company CL and Church & Dwight Co., Inc. CHD are the key consumer staple companies competing with Clorox in the global arena. Procter & Gamble uses a smart strategy when it comes to innovation. The company keeps improving its popular brands like Tide, Febreze and Mr. Clean by adding new features, better scents or easier packaging. At the same time, PG gives shoppers different choices depending on their budget. Colgate focuses on value-driven innovation, especially in home care and personal hygiene. The company regularly updates products with new scents, improved cleaning formulas and convenient packaging. Colgate also invests in sustainability, such as recyclable bottles and concentrated products. Its innovation is often designed to meet the needs of both budget-conscious and environmentally aware consumers. Church & Dwight is a key competitor to Clorox, known for its value-focused and niche household brands like OxiClean and Arm & Hammer. The company emphasizes cost-effective innovation, often targeting specific consumer needs with affordable, functional products. CHD competes directly with Clorox in laundry additives, cleaning sprays, and baking soda-based solutions. CLX's Price Performance, Valuation & Estimates Clorox shares have lost 25.5% year to date compared with the industry's growth of 2.2%. From a valuation standpoint, CLX trades at a forward price-to-earnings ratio of 18.0X, significantly below the industry's average of 20.23X. The Zacks Consensus Estimate for CLX's 2025 earnings implies year-over-year growth of 14.9%, whereas its 2026 earnings estimate suggests a year-over-year decline of 5.4%. The estimates for 2025 and 2026 have been unchanged in the past 30 days. Image Source: Zacks Investment Research CLX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report The Clorox Company (CLX): Free Stock Analysis Report Church & Dwight Co., Inc. (CHD): Free Stock Analysis Report
